author-photo

Clare Gilson

University College London

19

Papers

1550

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial

2020
Show All
- Source
- Cite
- Save
Citations (7)
The role of abiraterone acetate plus prednisone/prednisolone in high- and low-risk metastatic hormone sensitive prostate cancer

2019 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (1)
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

2019 Trials
Show All
- Source
- Cite
- Save
Citations (20)
Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 CSPC): A pilot molecular analysis in the STAMPEDE multi-center clinical trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
LBA4Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (22)
29PImplementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

2018 The Lancet
Show All
- Source
- Cite
- Save
Citations (482)
LBA31_PRAdding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Abiraterone for prostate cancer not previously treated with hormone therapy

2017 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (843)
Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)